Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination - Seite 3
The Novartis Foundation has been active in the fight against leprosy for 30 years, previously focusing on innovative social marketing programs to reduce the stigma attached to leprosy and supporting patient rehabilitation. The current focus of the foundation is to interrupt the transmission of the disease in an effort to go the last mile to elimination.
Disclaimer
This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "continued," "efforts," "commitment," "strategy,"
"focused," "calls for," "continues," "dream," "will," "goal," "launched," "pledge," "work to," "expected," "effort," "aim," or similar expressions. Such forward-looking statements reflect the
current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future
results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form
20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the
future.
About the Novartis Foundation
The Novartis Foundation is a philanthropic organization pioneering innovative healthcare models that can have a transformational impact on the health of the poorest populations. We
work hand-in-hand with our local and global partners to catalyze scalable and sustainable healthcare models to improve access and health outcomes, and to accelerate elimination of leprosy and
malaria by focusing on interventions that aim to interrupt transmission. Everything we do is grounded in evidence and innovation, and our work is a continuous cycle of evaluation, adaptation and
application. In 2015, the operational budget for the foundation was CHF 12 million and our programs reached 4.5 million people.
For more information, please visit:
www.novartisfoundation.org
www.youtube.com/novartisfoundation
Novartis Foundation is on Twitter. Sign up to follow @NovartisFDN at https://twitter.com/NovartisFDN
Lesen Sie auch
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best
meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net
sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies
employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com